БИОпрепараты. Профилактика, диагностика, лечение

Расширенный поиск

Безопасность биологических препаратов. Сообщение 1. Вопросы терминологии и классификации

Полный текст:

Об авторах

А. А. Солдатов
Научный центр экспертизы средств медицинского применения

Главный эксперт Управления экспертизы аллергенов, цитокинов и других иммуномодуляторов Центра экспертизы и контроля МИБП, д-р мед. наук

Ж. И. Авдеева
Научный центр экспертизы средств медицинского применения

Главный эксперт Управления экспертизы аллергенов, цитокинов и других иммуномодуляторов Центра экспертизы и контроля МИБП, д-р мед. наук, профессор

Ю. В. Олефир
Научный центр экспертизы средств медицинского применения
Генеральный директор, д-р мед. наук

В. А. Меркулов
Научный центр экспертизы средств медицинского применения
Заместитель генерального директора по экспертизе лекарственных средств, д-р мед. наук, профессор

В. П. Бондарев
Научный центр экспертизы средств медицинского применения
Директор Центра экспертизы и контроля МИБП, д-р мед. наук, профессор

Список литературы

1. Public Health Services Act 42 U. S. C. § 262(i).

2. Directive 2001/83/EC of the European parliament and of the council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 67).

3. Pichler WJ. Adverse side-effects to biological agents. Allergy; 2006; 61: 912-20.

4. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008; 7(1): 21 - 39.

5. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Q5C: Quality of biotechnological products: Stability testing of biotechnological/biological products, Nov. 30, 1995.

6. Солдатов АА, Авдеева ЖИ, Алпатова НА, Медуницын НВ, Киселевский МВ, Лысикова СЛ. и др. Проблемы регистрации биологических неоригинальных препаратов. Биопрепараты 2014; (4): 24-36.

7. Wax PM. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med. 1995; 122(6): 456-61.

8. Stephens T, Brynner R. Dark Remedy. The Impact of Thalidomide and its Revival as a Vital Medicine. Cambridge, Massachusetts: Perseus Publishing; 2001.

9. Dukes MNG. The seven pillars of foolishness. In: Dukes MNG, editor. Side Effects of Drugs. Annual 8. Amsterdam: Elsevier; 1984. P. xvii-xxiii.

10. Shah RR. Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol. 2002; 16(2): 119-24.

11. World Health Organization. The Importance of Pharmacovigilance. Safety Monitoring of Medicinal Products. Chapter 2. A Short History of Involvement in Drug Safety Monitoring by WHO. Available from:

12. Available from: v 4.03.

13. Ferner RE, Butt TF. Adverse drug reactions. Med. 2012; 40: 366-70.

14. Rawlins M, Thompson W. Mechanisms of adverse drug reactions. In: Davies D, ed. Textbook of adverse drug reactions. New York: Oxford University Press; 1991. P. 18-45.

15. Ebbers HC, Al-Temimi E, Moors EHM, Mantel-Teeuwisse AK, Schellekens H, Leufkens HGM. Differences Between Post-Authorization Adverse Drug Reactions of Biopharmaceuticals and Small Molecules. BioDrugs 2013; 27(2): 167-74.

16. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008; 300: 1887-96.

17. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003; 139: 683-93.

18. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005; 23: 5235-46.

19. Danese S, Fiocchi C. Platelet activation and the CD40 / CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol 2005; 25: 103-21.

20. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003; 138: 807-11.

21. Kasahara A, Hiraide A, Tomita N, Iwahashi H, Imagawa A, Ohguro N, et al. Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. J Gastroenterol. 2004; 39: 1106-09.

22. Sherer K, Spoerl D, Bircher AJ. Adverse drug reactions to biologics. JDDG 2010; (8): 411-26.

23. Clarke JB. Mechanisms of adverse drug reactions to biologics. In: Uetrecht J, ed. Adverse Drug Reactions. Handbook of Experimental Pharmacology. New York: Springer; 2010. P. 453-74.

24. Aronson JK, Ferner RE. Joining the DoTS: new approach to classify adverse drug reactions. BMJ 2003; 327: 1222-25.

25. Napoleone E. Children and ADRs (Adverse Drug Reactions). Ital. J. Pediat. 2011; 36: e1-e5.

26. Horen B, Montastruc JL. Adverse drug reactions and off-label drug use in pediatric outpatients. Br J Clin Pharmacol. 2002; 5(4): 665-70.

27. Pichler WJ, Adam J, Daubner B, Gentinetta T, Keller M, Yerly D. Drug Hypersensitivity Reactions: Pathomechanism and Clinical Symptoms. Med Clin № Am. 2010; 94: 645-64.

28. Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 2002; 118: 728-33.

29. Britschgi M, Steiner UC, Schmid S, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest. 2001; 107: 1433-41.

30. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol. 2002; 2: 301-5.

31. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 9 August, 2006. Available from:

32. Barbaud A., Granel F., Waton J., Poreaux C. How to manage hypersensitivity reactions to biological agents? Eur J Dermatol. 2011; 21 (5): 667-74.


Для цитирования:

Солдатов А.А., Авдеева Ж.И., Олефир Ю.В., Меркулов В.А., Бондарев В.П. Безопасность биологических препаратов. Сообщение 1. Вопросы терминологии и классификации. БИОпрепараты. Профилактика, диагностика, лечение. 2016;16(1):14-26.

For citation:

Soldatov A.A., Avdeeva Z.I., Olefir Yu.V., Merkulov V.A., Bondarev V.P. Safety of biological preparations. Report 1. Terminology and classification issues. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(1):14-26. (In Russ.)

Просмотров: 820

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2221-996X (Print)
ISSN 2619-1156 (Online)